Cancer Talk

News

Nigerian Hematologist Receives Vital Training at Roswell Park

Thanks to a Visitor Training Program grant from the American Society of Hematology (ASH) awarded to Roswell Park hematopathlogist Vishala Neppalli, MD, visiting physician Tamunomieibi Wakama, MD, can now perform crucial pathology analyses, essential to accurate diagnosis and treatment of his pati

News

New Approach, New Hope: State Investment Will Fast-Track Innovative Roswell Park Research in Ovarian Cancer

Researchers at Roswell Park Cancer Institute have received a prestigious grant of nearly $12 million from the New York State Stem Cell Science Program to develop new therapies for advanced ovarian cancer. The four-year, $11.9 million grant to RPCI is one of three new state awards totaling $36 million to support innovative approaches for developing stem-cell based therapies for diseases that are notoriously hard to treat.
News

Roswell Park Gynecologic Oncologists Providing Care in Jamestown

Roswell Park Comprehensive Cancer Center physicians with specialized training and expertise in gynecologic oncology are now providing care to women in the Jamestown area. Drs. Peter Frederick, Kunle Odunsi and Emese Zsiros are available for appointments with new or existing patients at Jamestown Medical Oncology Hematology, a Roswell Park community cancer practice located at 21 Porter Ave., Jamestown, N.Y. 14701.

News

Roswell Park Surgeons Compile New Anthology on Surgery for Stomach, Esophageal Cancers

Two Roswell Park Cancer Institute surgeons have produced a new, comprehensive guide on minimally invasive surgical approaches for treating cancers of the stomach and esophagus. Published by Springer, the anthology, “Minimally Invasive Foregut Surgery for Malignancy: Principles and Practice,” was edited by Steven Hochwald, MD, FACS, Chief of Gastrointestinal Surgery and Vice Chair of the Department of Surgical Oncology, and Moshim Kukar, MD, a newly appointed faculty member in the RPCI Department of Surgical Oncology.
News

Roswell Park Study Suggests Additional Applications for FL118 as Personalized Therapy for Cancer

A team led by Fengzhi Li, PhD, and Xinjiang Wang, PhD, of Roswell Park Cancer Institute has reported new findings regarding therapeutic targets of the novel anticancer agent FL118. Previous studies from these researchers have showed that FL118 induces cancer cell death, or apoptosis, by inhibiting expression of multiple cell-survival proteins (survivin, Mcl-1, XIAP or cIAP2).